Molecular testing in colorectal carcinoma

Reetesh K. Pai, Rish Pai

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

An estimated 150,000 individuals are diagnosed with colorectal carcinoma (CRC) each year, and approximately 50,000 will die from this disease, making CRC the third leading cause of cancer deaths in the United States. For this reason, an enormous amount of effort has been spent to understand the molecular pathogenesis of this disease and to develop screening tests and prognostic markers. In the last 10 years, there has been a revolution in the understanding of CRC due to the identification of multiple distinct molecular pathways. With the introduction of biologic agents that target particular subtypes of CRC, molecular analysis of CRC is becoming standard of care in surgical pathology. In this context, the authors first describe the multiple molecular pathways leading to CRC and then discuss the role of molecular testing in the diagnosis of Lynch syndrome (formerly hereditary nonpolyposis colorectal carcinoma), prognosis, and therapy.

Original languageEnglish (US)
Pages (from-to)429-445
Number of pages17
JournalSurgical Pathology Clinics
Volume3
Issue number2
DOIs
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Hereditary Nonpolyposis Colorectal Neoplasms
Surgical Pathology
Biological Factors
Standard of Care
Cause of Death
Neoplasms

Keywords

  • Colorectal carcinoma
  • KRAS
  • Lynch syndrome
  • Molecular testing

ASJC Scopus subject areas

  • Surgery
  • Pathology and Forensic Medicine

Cite this

Molecular testing in colorectal carcinoma. / Pai, Reetesh K.; Pai, Rish.

In: Surgical Pathology Clinics, Vol. 3, No. 2, 01.06.2010, p. 429-445.

Research output: Contribution to journalReview article

Pai, Reetesh K. ; Pai, Rish. / Molecular testing in colorectal carcinoma. In: Surgical Pathology Clinics. 2010 ; Vol. 3, No. 2. pp. 429-445.
@article{4116e9ec8f214caf94a289172ffcf1d5,
title = "Molecular testing in colorectal carcinoma",
abstract = "An estimated 150,000 individuals are diagnosed with colorectal carcinoma (CRC) each year, and approximately 50,000 will die from this disease, making CRC the third leading cause of cancer deaths in the United States. For this reason, an enormous amount of effort has been spent to understand the molecular pathogenesis of this disease and to develop screening tests and prognostic markers. In the last 10 years, there has been a revolution in the understanding of CRC due to the identification of multiple distinct molecular pathways. With the introduction of biologic agents that target particular subtypes of CRC, molecular analysis of CRC is becoming standard of care in surgical pathology. In this context, the authors first describe the multiple molecular pathways leading to CRC and then discuss the role of molecular testing in the diagnosis of Lynch syndrome (formerly hereditary nonpolyposis colorectal carcinoma), prognosis, and therapy.",
keywords = "Colorectal carcinoma, KRAS, Lynch syndrome, Molecular testing",
author = "Pai, {Reetesh K.} and Rish Pai",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.path.2010.05.005",
language = "English (US)",
volume = "3",
pages = "429--445",
journal = "Surgical Pathology Clinics",
issn = "1875-9181",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Molecular testing in colorectal carcinoma

AU - Pai, Reetesh K.

AU - Pai, Rish

PY - 2010/6/1

Y1 - 2010/6/1

N2 - An estimated 150,000 individuals are diagnosed with colorectal carcinoma (CRC) each year, and approximately 50,000 will die from this disease, making CRC the third leading cause of cancer deaths in the United States. For this reason, an enormous amount of effort has been spent to understand the molecular pathogenesis of this disease and to develop screening tests and prognostic markers. In the last 10 years, there has been a revolution in the understanding of CRC due to the identification of multiple distinct molecular pathways. With the introduction of biologic agents that target particular subtypes of CRC, molecular analysis of CRC is becoming standard of care in surgical pathology. In this context, the authors first describe the multiple molecular pathways leading to CRC and then discuss the role of molecular testing in the diagnosis of Lynch syndrome (formerly hereditary nonpolyposis colorectal carcinoma), prognosis, and therapy.

AB - An estimated 150,000 individuals are diagnosed with colorectal carcinoma (CRC) each year, and approximately 50,000 will die from this disease, making CRC the third leading cause of cancer deaths in the United States. For this reason, an enormous amount of effort has been spent to understand the molecular pathogenesis of this disease and to develop screening tests and prognostic markers. In the last 10 years, there has been a revolution in the understanding of CRC due to the identification of multiple distinct molecular pathways. With the introduction of biologic agents that target particular subtypes of CRC, molecular analysis of CRC is becoming standard of care in surgical pathology. In this context, the authors first describe the multiple molecular pathways leading to CRC and then discuss the role of molecular testing in the diagnosis of Lynch syndrome (formerly hereditary nonpolyposis colorectal carcinoma), prognosis, and therapy.

KW - Colorectal carcinoma

KW - KRAS

KW - Lynch syndrome

KW - Molecular testing

UR - http://www.scopus.com/inward/record.url?scp=77955645798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955645798&partnerID=8YFLogxK

U2 - 10.1016/j.path.2010.05.005

DO - 10.1016/j.path.2010.05.005

M3 - Review article

AN - SCOPUS:77955645798

VL - 3

SP - 429

EP - 445

JO - Surgical Pathology Clinics

JF - Surgical Pathology Clinics

SN - 1875-9181

IS - 2

ER -